Palvella Therapeutics GAAP EPS of -$3.71 misses by $0.19 [Seeking Alpha]
Palvella Therapeutics, Inc. (PVLA)
Company Research
Source: Seeking Alpha
Pro forma cash of approximately $274 million as of December 31, 2025 reflects approximate net proceeds of $215.8 million from a February 2026 equity financing; cash and cash equivalents as of December 31, 2025 were $58.0 million. Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters Sign Up More on Palvella Therapeutics Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag Palvella Therapeutics stock rises on $200M share offering Seeking Alpha's Quant Rating on Palvella Therapeutics Historical earnings data for Palvella Therapeutics Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
PVLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVLA alerts
High impacting Palvella Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PVLA
News
- Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of DirectorsGlobeNewswire
- Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of SalesGlobeNewswire
- Palvella's Phase III Success And Fast Track Status Test Current Valuation [Yahoo! Finance]Yahoo! Finance
- Palvella Therapeutics (PVLA) had its price target raised by Chardan Capital from $210.00 to $240.00. They now have a "buy" rating on the stock.MarketBeat
- Palvella Therapeutics Inc (PVLA) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
PVLA
Earnings
- 3/31/26 - Miss
PVLA
Sec Filings
- 4/17/26 - Form 4
- 4/15/26 - Form 4
- 4/15/26 - Form 3
- PVLA's page on the SEC website